ABBV-066 / Risankizumab, Risankizumab, Matching Placebo for 90 mg solution for injection, ABBV-066, Matching placebo for 180 mg solution for injection
M16-194
Phase 3 small_molecule active
Quick answer
ABBV-066 / Risankizumab, Risankizumab, Matching Placebo for 90 mg solution for injection, ABBV-066, Matching placebo for 180 mg solution for injection for Crohn's disease is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Crohn's disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active